Key result
Pravastatin 40 mg daily initiated early after acute coronary syndromes significantly increased endothelium-dependent flow-mediated dilatation to 7.0% compared to 5.84% with placebo (P=0.02).
Why the study?
Does pravastatin 40 mg daily improve endothelial function in patients with acute coronary syndromes and elevated cholesterol?
Population
60 patients with acute myocardial infarction or unstable angina and total cholesterol levels at admission…
Comparison
Pravastatin 40 mg daily for 6 weeks vs Placebo for 6 weeks
Design
RCT, randomized
Follow-up
6 weeks
Authors
Loading...
Supports early pravastatin post-ACS to improve endothelial function; extends evidence for rapid pleiotropic effects.
RCT (n=60)
Does pravastatin 40 mg daily improve endothelial function in patients with acute coronary syndromes and elevated cholesterol?
Absolute Event Rate: 7% vs 5.84%
p-value: p=0.02
Early initiation of pravastatin after acute coronary syndromes rapidly improves endothelial function within 6 weeks.
Dupuis et al. (1999) conducted an RCT in Acute coronary syndromes (acute myocardial infarction or unstable angina) (n=60). Pravastatin vs. Placebo was evaluated on Endothelium-dependent flow-mediated dilatation (FMD) (p=0.02). Pravastatin 40 mg daily initiated early after acute coronary syndromes significantly increased endothelium-dependent flow-mediated dilatation to 7.0% compared to 5.84% with placebo (P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: